Rivaroxaban versus Warfarin in Nonvavular Atrial Fibrillation
NEJM 365:883-891, 952, Patel, M.R.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Acutely Injured Patients on Dabigatran
NEJM 365:2039-2040, Cotton, B.A.,et al, 2011
New Alternative to Warfarin May Help Reduce Stroke Risk in Patients With AF
JAMA 305:25-26, Mitka,M., 2011
Dabigatran Etexilate - A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity
Thromb Hemost 103:1116-1127, van Ryn,J.,et al, 2010
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial
Lancet 376:975-983, Wallentin,L.,et al, 2010
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Anticoagulation After Cardioembolic Stroke: To Bridge or Not to Bridge
Arch Neurol 65:1169-1173,1157, Hallevi,H.,et al., 2008
Antithrombotic and Interventional Treatment Options in Cardioembolic Transient Ischaemic Attack and Ischaemic Stroke
JNNP 78:14-24, McCabe,D.J.H. &Rakhit,R.D., 2007
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
The Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin for the Prevention of Venous Thromboembolism After Acute Ischaemic Stroke (PREVAIL Study): An Open-Label Randomised Comparison
Lancet 369:1347-1355, Sherman,D.G.,et al, 2007
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trial
Stroke 38:2965-2971, Ford,G.A.,et al, 2007
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005
Ximelagatran--Promises and Concerns
JAMA 293:736-739, Gurewich,V., 2005
Direct Thrombin Inhibition
Stroke 35:1519-1522, Elkind,M.S.V. &Sacco,R.L., 2004
Anticoagulants for Acute Ischemic Stroke
Stroke 35:2916-2917, Sandercock,P.,et al, 2004
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Spinal and Epidural Hematoma and Low-Molecular-Weight Heparin
NEJM 338:1774-1775, Wysowski,D.K.,et al, 1998
Anticoagulation Therapy in Pediatric Patients with Sinovenous Thrombosis,A Cohort Study
Arch Neurol 55:1533-1537, deVeber,G.,et al, 1998
Epidural/Spinal Hematoma with Low Molecular Weight Heparin & Spinal/Epidural Anesth or Spinal Puncture
FDA Advisory, Dec 151997., , 1997